Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobevibart + elebsiran versus bulevirtide in chronic hepatitis D
NL-OMON58792Phase 2Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis D (HDV) comparing Tobevibart + elebsiran with Bulevirtide (2 arms). Primary endpoints: HDV RNA below LLOQ and target not detected at Week 48, HDV RNA below LLOQ and target not detected 24 weeks after end of treatment interruption and 1 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
tobevibartelebsiranbulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NL-OMON58792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58792.